CLEVELAND, Ohio — A new Cleveland Clinic spin-off company that’s developing a test to predict cardiac risk has received a $2.5 million investment.
The source of the investment in newly created Cleveland Heartlab LLC was not disclosed in a statement from the Cleveland Clinic.
The company plans to use the investment to bolster its sales and marketing efforts and expand its clinical laboratory, according to the statement. Heartlab’s lead product, CardioMPO, has received approval from the U.S. Food and Drug Administration. CardioMPO is a diagnostic test used to predict a patient’s near-term heart attack and cardiac death risk.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The Web site of another Cleveland Clinic spin-off, PrognostiX, says that company is marketing the CardioMPO product. It’s unclear what relationship, if any, exists between the two companies.
A Cleveland Clinic spokesman wasn’t available for comment.
Heartlab is also developing a product to detect and measure HDL, also known as “good cholesterol,” and another to measure the anti-inflammatory effects of statin therapy, which lowers “bad” cholesterol, according to the statement.
